SAVE THE DATE FOR the second bioRN C-Level Circle– an exclusive format for managing directors from the bioRN network.Date: Tuesday, 3rd February 2026Time: 6:00 – 9:00 pmHost: Dr. Claus Kremoser, Managing Director WMT AG Costs: approx. €30 per person. A selection of food and drinks will be provided on a self-pay basis. Agenda: The Agenda will be announced soon. Each event is dedicated to a current hot topic with direct relevance for decision-makers in the life science industry.The C- Level Circle is aimed exclusively at managing directors of the bioRN member companies, partners and friends of bioRN Life Science Cluster and creates space for trusting exchange, peer coaching and strategic discussions. Location: The Klinker Café and Event-Location, Bahnbetriebswerk 5, 69115 Heidelberg will open its doors for us exclusively. Take advantage of this opportunity to get to know other ‘C's’ in the region better, share experiences and take away new ideas. To help us plan, please register at this link.
Please understand that we will review the registrations and send you a response as soon as possible. Looking foward to meet you there!
In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]
ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics
HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]
AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million. The acquisition adds to Amgen’s […]
You are currently viewing a placeholder content from Mailchimp. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.